AstraZeneca's Different Thinking On Weight Management Behind Eccogene Deal

Sharon Barr, AstraZeneca’s executive vice president, biopharmaceuticals R&D, in an interview with Scrip, outlines how the company is using a holistic approach to define a new competitive landscape in the weight loss sector. She also sees new frontiers for the firm and its potential partners both in China and beyond to jointly explore aimed at maintaining healthy muscle mass while decreasing body fat.